OPDIVO ZENCEIVE Trademark

Trademark Overview

On Wednesday, November 6, 2019, a trademark application was filed for OPDIVO ZENCEIVE with the United States Patent and Trademark Office. The USPTO has given the OPDIVO ZENCEIVE trademark a serial number of 88681638. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 25, 2023. This trademark is owned by Bristol-Myers Squibb Company. The OPDIVO ZENCEIVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; P...
opdivo zenceive

General Information

Serial Number88681638
Word MarkOPDIVO ZENCEIVE
Filing DateWednesday, November 6, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 25, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 28, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 13, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Monday, September 25, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 25, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, February 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 13, 2023SOU EXTENSION 2 GRANTED
Monday, February 13, 2023SOU EXTENSION 2 FILED
Monday, February 13, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU EXTENSION 1 GRANTED
Wednesday, July 27, 2022SOU EXTENSION 1 FILED
Wednesday, July 27, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, February 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 28, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 28, 2021PUBLISHED FOR OPPOSITION
Wednesday, December 8, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 18, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 19, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 19, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 18, 2021ASSIGNED TO LIE
Tuesday, October 12, 2021ASSIGNED TO LIE
Monday, October 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, April 3, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, April 3, 2021NON-FINAL ACTION E-MAILED
Saturday, April 3, 2021NON-FINAL ACTION WRITTEN
Wednesday, March 3, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 2, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 2, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, September 6, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, September 6, 2020NON-FINAL ACTION E-MAILED
Sunday, September 6, 2020NON-FINAL ACTION WRITTEN
Wednesday, August 5, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 5, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 5, 2020NON-FINAL ACTION E-MAILED
Wednesday, February 5, 2020NON-FINAL ACTION WRITTEN
Friday, January 24, 2020ASSIGNED TO EXAMINER
Wednesday, November 13, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 9, 2019NEW APPLICATION ENTERED

Related Keywords

zenceive opdivo diseases pharmaceutical human preparations anti disorders system cancer treatment immune